ClinicalTrials.gg
Status unknownNCT04326881Updated Mar 30, 2020

A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects

A Phase 1 interventional study of SHR-1314 in Pharmacokinetic, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study will be a single-center, randomized, parallel, open-label, single dosing bridging study in healthy subjects to evaluate the pharmacokinetics and safety of two formulations of SHR-1314.

Read the detailed description

This study will be a single-center, randomized, parallel, open-label, single dosing (SHR-1314 240mg) bridging study in healthy subjects to evaluate the pharmacokinetics and safety of two formulations of SHR-1314.

The study will consist of a 14-days screening period (-14\~-1 days); an observation period (1-3 days) and the follow-up period (4-113 days); Subjects will be randomly assigned to three group.

02

Conditions studied

  • Pharmacokinetic
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained before any assessment is performed.Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations.
  • Men or women at least 18 years and no more than 45 years of age at time of screening.
  • Men with a body weight ≥50 kg or women with a body weight ≥45kg, with range from 18 to 25.
  • Subjects with normal physical examination results and with normal laboratory results (blood, chemistry, urine, drug screening, coagulation function test), and X-ray chest test are normal or with certain abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  • Presence of significant medical problems, with investigator's judge that not proper to participate clinical study
  • History of to any of study drug constituent
  • History or current infection with (HIV) or ; or current infection or syphilis
  • History of lymphoproliferative disease or any known or history of malignancy of any organ system within the past 5 years
  • History of chronic or recurrent infectious disease, or evidence of active or latent tuberculosis infection.
  • Those who have participated in any clinical study for any drug or medical device within 3 months before screening
  • Those who have been vaccinated with within 12 weeks prior to screening
  • History or evidence of ongoing alcohol or drug abuse, within the last six months before Baseline.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Subjects judged by the investigator as unsuitable for participating in this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SHR-1314 A

    single dosing SHR-1314 A

    Drug: SHR-1314

  • Experimental
    SHR-1314 B

    single dosing SHR-1314 B

    Drug: SHR-1314

  • Experimental
    SHR-1314 C

    single dosing SHR-1314 C

    Drug: SHR-1314

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-last: Area under the serum concentration-time curve from time zero to the last measurable concentration

    Compare the AUC0-last of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

  2. Cmax: Observed maximum serum concentration

    Compare the Cmax of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

  3. AUC0-∞: Area under the serum concentration-time curve from time zero to infinity

    Compare the AUC0-∞ of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

Secondary outcomes

  1. Tmax : Time at which observed maximum concentration occurs

    Compare the Tmax of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

  2. CL/F: Apparent clearance

    Compare the CL/F of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

  3. t1/2: Terminal half-life

    Compare the t1/2 of 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

  4. Incidence and severity of adverse events (AEs).

    Compare Incidence and severity of AE at 240mg subcutaneous injection of two specifications of SHR-1314 injection in healthy subjects

    Time frame: from Day1 to Day113

  5. Anti-drug Antibodies (ADAs)

    Incidence of development of Anti-drug Antibodies (ADAs) during the course of the study.

    Time frame: from Day1 to Day113

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2020; primary completion for Jul 2020, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2020
First posted
Mar 30, 2020
StartEst.
Apr 7, 2020
Primary completionEst.
Jul 7, 2020
CompletionEst.
Nov 30, 2020
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04326881
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Apr 7, 2020 (estimated)
Primary completion
Jul 7, 2020 (estimated)
Completion
Nov 30, 2020 (estimated)
Last update
Mar 30, 2020

Study contacts

Qian Xu, Ph.D.
Contact
xuqian@hrglobe.cn
0186 021-68868370
Jianwen Chen, Ph.D.
Contact
0186 021-68868370

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion